For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  GHRP-2
Performance & Musclephase_2_3

GHRP-2

Pralmorelin
Performance & Muscle
ASK VERA ABOUT THIS ↗BROWSE THE CATALOG ↗
Category
Performance & Muscle
Evidence grade
B
PubMed records
221
Female-tagged
80
Sex-analysis
2
CAS
—
B
Evidence grade B, Phase 2/3 human trial evidence across 221 indexed studies (mixed-sex). How grades work →
Female evidence: Extrapolated
GHRP-2: of 221 PubMed records, 80 are tagged as including female subjects and 2 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic growth-hormone secretagogue, a small peptide engineered to act on the pathways that govern pituitary growth-hormone output. Its compact, synthetic structure gives it a research-friendly profile as a tool compound in endocrine investigation.

In preclinical and in-vitro systems, GHRP-2 has been studied for its role in stimulating growth-hormone release from the pituitary, acting through the growth-hormone secretagogue signaling axis. Researchers examining the neuroendocrine control of growth-hormone secretion have used it as a research material to characterize secretagogue-driven release and its interaction with related regulatory pathways.

What makes GHRP-2 a useful entry for an endocrine research catalog is its well-defined action as a secretagogue, which lets investigators isolate this arm of growth-hormone regulation. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women. Supplied for in-vitro and laboratory research only.

Summary

GHRP-2 (pralmorelin) is a growth-hormone secretagogue approved in Japan as a diagnostic agent for growth-hormone deficiency. Human studies have included women, but they focus on the GH axis and are not analyzed for female-specific outcomes.

Evidence in women

Menstrual cycle
Unstudied
The GH response is estrogen-sensitive, but pralmorelin testing has not been standardized across cycle phases.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data.
Hormonal interactions
Unstudied
No controlled data on interactions with estrogen or contraceptives.
Perimenopause & menopause
Unstudied
No perimenopausal or menopausal studies.
Sex differences
Unstudied
Women were included in diagnostic studies, but results were not analyzed by sex.

Mechanism

A potent ghrelin/GHS-receptor agonist that triggers pituitary growth-hormone release.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)A single ~100 µg intravenous dose is used in the approved Japanese GH-stimulation test; no approved therapeutic dose.
Routesintravenous, subcutaneous, intranasal
Female-specific dosingNot established

Contraindications: active malignancy (GH-axis stimulation, theoretical)

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

increased appetitetransient cortisol and prolactin increaseflushing

GHRP-2 reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for GHRP-2

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from GHRP-2's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is GHRP-2?

GHRP-2, also known as Pralmorelin, is a research compound in our performance muscle category. GHRP-2 (pralmorelin) is a growth-hormone secretagogue approved in Japan as a diagnostic agent for growth-hormone deficiency.

Is GHRP-2 studied in women?

GHRP-2: of 221 PubMed records, 80 are tagged as including female subjects and 2 carry a sex-analysis tag. We grade this extrapolated: women appear in the record, but no study is tagged for a sex-specific analysis, so female-relevant conclusions are inferred from mixed or male data rather than measured in women. See our methodology.

Has GHRP-2 been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does GHRP-2 have, and why?

GHRP-2 carries evidence grade B. Phase 2/3 human trial evidence across 221 indexed studies (mixed-sex).. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for GHRP-2?

No. A female-specific dose for GHRP-2 is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is GHRP-2 administered in research?

In the published literature, GHRP-2 is administered via intravenous, subcutaneous, intranasal. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for GHRP-2?

Effects reported in the research literature include increased appetite, transient cortisol and prolactin increase, flushing. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should GHRP-2 be stored and handled?

GHRP-2 sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy GHRP-2 for research?

GHRP-2 is not currently listed by our research-use partner, Aurevena Research, but their catalog carries related compounds. Code research15 applies 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Browse the Aurevena catalog
Research-use supplier: GHRP-2 isn't currently listed by our research-use vendor. Their catalog carries related compounds. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Browse the catalog →

Citations (PMID)

15230633 · 28400207

Related peptides

2X Blend CJC-1295 WO DAC (5mg) / Ipamorelin·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
ACE-031C
ACE-031: of 48 PubMed records, 11 are tagged as including female subjects and 0 carry a sex-analysis tag.
AICARB
AICAR: of 2,496 PubMed records, 329 are tagged as including female subjects and 2 carry a sex-analysis tag.
CJC-1295 with DACC
CJC-1295 with DAC: of 32 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.